Aging, longevity, inflammation, and cancer

Annals of the New York Academy of Sciences

Volumn 1028, Issue , 2004, Pages 1-13

  Caruso, Calogero ^a   Lio, Domenico ^a   Cavallone, Luca ^a,b   Franceschi, Claudio ^b,c,d  

^a UNIVERSITY OF PALERMO   (Italy)

^b Istituto Nazionale Ricovero e Cura Anziani   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Dipto di Patologia Sperimentale   (Italy)

Author keywords

Aging; Cancer; IL 10; IL 6; Longevity

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6;

AGING; CANCER; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA POLYMORPHISM; GENOTYPE; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFLAMMATION; LONGEVITY; MORTALITY; PLEIOTROPY; TUMOR GROWTH;

EID: 14944354861     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1322.001     Document Type: Conference Paper

References (69)

1. DEPINHO, R.A. 2000. The age of cancer. Nature 408: 248-254.
2. PARKIN, D.M. et al. 1997. Cancer. Incidence in Five Continents, Vol. VII. IARC Sci. Publication No. 143. IARC. Lyon, France.
3. REPETTO, L. et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur. J. Cancer 39: 870-880.
4. FRANCESCHI, C. et al. 1995. The immunology of exceptional individuals: the lesson of centenarians. Immunol. Today 16: 12-16.
5. MIYAISHI, O. et al. 2000. Cancer incidence in old age. Mech. Ageing Dev. 117: 47-55.
6. STANTA, G. et al. 1997. Cancer of the oldest old: what we have learned from autopsy studies. Clin. Geriatr. Med. 13: 55-68.
7. PIANTANELLI, L. 1988. Cancer and aging: from the kinetics of biological parameters to the kinetics of cancer incidence and mortality. Ann. N.Y Acad. Sci. 521: 99-109.
8. SMITH, D.W.E. 1999. Resistance to causes of death: a study of cancer mortality resistance in the oldest old. In Research and Perspectives in Longevity: The Paradoxes of Longevity. J.M. Robine et al., Eds.: 61-71. Springer. Berlin.
9. BONAFÈ, M. et al. 2002. What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. Exp. Gerontol. 37: 1263-1271.
10. FRANCESCHI C., et al. 2000. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann. N.Y. Acad. Sci. 908: 244-254.
11. BRUUNSGAARD, H. et al. 2001. Aging and proinflammatory cytokines. Curr. Opin. Hematol. 8: 131-6.
12. BROD, S.A. 2000. Unregulated inflammation shortens human functional longevity. Inflamm. Res. 49: 561-570.
13. PAWELEC, G. et al. 2002. T cells and aging: 2002 update. Front. Biosci. 7: 1056-1183.
14. CANDORE, G. et al. 2003. Immunological and immunogenetic markers of successful and unsuccessful ageing. Adv. Cell Aging Gerontol. 13: 29-45.
15. BRIGATI, C. et al. 2002. Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis 19: 247-258.
16. BALKWILL, F. & A. MANTOVANI. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545.
17. BONAFÈ, M. et al. 2001. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur. J. Immunol. 31: 2357-2361.
18. LIO, D. et al. 2002. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun. 3: 30-33.
19. LIO, D. et al. 2003. Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. J. Med. Genet. 40: 296-299.
20. BIDWELL, J. et al. 2001. Cytokine gene polymorphism in human disease: on-line data-bases, supplement 1. Genes Immun. 2: 61-70.
21. BIDWELL, J. et al. 1999. Cytokine gene polymorphism in human disease, on-line databases. Genes Immun. 1: 3-19
22. REYNARD, M.P. et al. 2000. Allele frequencies of polymorphisms of the tumour necrosis factor-α, interleukin-10, interferon-γ and interleukin-2 genes in a North European Caucasoid group from the UK. Eur. J. Immunogenet. 27: 241-249.
23. TURNER, D.M. et al. 1997. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 24: 1-8.
24. CRAWLEY, E. et al. 1999. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 42: 1101-1108.
25. SUAREZ, A. 2003. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 75: 711-717.
26. LIO, D. & C. CARUSO. 2004. IL-10, genetic polymorphism and its relevance to age-related diseases. In Interleukin-10. F. Marincola, Ed. Landes Bioscience. Georgetown, NW, Washington, DC. Epup 3.4: 1-14.
27. DUMMER, W. et al. 1995. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 5: 67-68.
28. MCCARRON, S.L. et al. 2002. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 62: 3369-3372.
29. HUANG, S. et al. 1999. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J. Interferon Cytokine Res. 9: 697-703.
30. HOWELL, W.M. et al. 2001. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2: 25-31.
31. MARTINEZ-ESCRIBANO, J.A. et al. 2002. Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res. 12: 465-469.
32. HOWELL, W.M. et al. 2002. Gene polymorphisms, inflammatory diseases and cancer. Proc. Nutr. Soc. 61: 447-56.
33. EL-OMAR, E.M. et al. 2003. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124: 1193-1201.
34. SHIN, H.D. et al. 2003. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum. Mol. Genet. 12: 901-906.
35. GIORDANI, L. et al. 2003. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin. Chem. 49: 1664-1667.
36. SATO, K. et al. 1999. Extracellular signal-regulated kinase stress-activated protein kinase/c-jun N-terminal kinase and p38 Mapk are involved in IL-10 mediated selective repression of TNF-alpha induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J. Immunol. 162: 3865-3872.
37. MOORE, K.W. et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
38. UROSEVIC, M. & R. DUMMER. 2003. HLA-G and IL-10 expression in human cancer: different stories with the same message. Semin. Cancer Biol. 13: 337-342.
39. SMITH, E.M. et al. 1999. IL-10 as a mediator in the HPA axis and brain. J. Neuroimmunol. 100: 140-148.
40. FISHMAN, D. et al. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102: 1369-1376.
41. ISHIHARA, K. & T. HIRANO. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 13: 357-368.
42. HUTCHINS, D. & C.M. STEEL. 1994. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int. J. Cancer. 58: 80-84.
43. COHEN, T. et al. 1996. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271: 736-741.
44. BELLUCO, C. et al. 2003. -174 G→C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin. Cancer Res. 9: 2173-2176.
45. BACHELOT, T. et al. 2003. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer. 88: 1721-1726.
46. BASOLO, F. et al. 1996. Expression of and response to interleukin 6 (IL6) in human mammary tumors. Cancer Res. 56: 3118-22.
47. FONTANINI, G. et al. 1999. Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. Br. J. Cancer. 80: 579-584.
48. KARCZEWSKA, A. et al. 2000. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer 88: 2061-2071.
49. HEFLER, L.A. et al. 2003. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 63: 3066-3068.
50. DEMICHELE, A. et al. 2003. Interleukin-6 -174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 63: 8051-8056.
51. IACOPETTA, B. et al. 2004. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br. J. Cancer. 90: 419-422.
52. LANDI, S. et al. Bellvitge Colorectal Cancer Study Group. 2003. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 63: 3560-3566.
53. BELLUCO, C. et al. 2000. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann. Surg. Oncol. 7: 133-138.
54. CHUNG, Y.C. & Y.F. CHANG. 2003. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol. 83: 222-226.
55. KAMIMURA, D. et al. 2003. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149: 1-38
56. PAWELEC, G. et al. 2002. Is human immunosenescence clinically relevant? Looking for immunological risk phenotypes. Trends Immunol. 23: 330-332.
57. WANG, X.Y. et al. 2001. Lack of association between human longevity and polymorphisms of IL-1 cluster, IL-6, IL-10 and TNF-alpha genes in Finnish nonagenarians. Mech. Ageing Dev. 123: 29-38.
58. REA, I.M. et al. 2003. Interleukin-6-gene C/G 174 polymorphism in nonagenarian and octogenarian subjects in the BELFAST study. Reciprocal effects on IL-6, soluble IL-6 receptor and for IL-10 in serum and monocyte supernatants. Mech. Ageing Dev. 124: 555-561.
59. ROSS, O.A. et al. 2003. Study of age-association with cytokine gene polymorphisms in an aged Irish population. Mech. Ageing Dev. 124: 199-206.
60. PES, G.M. et al. 2004 Association between longevity and cytokine gene polymorphisms: a study in Sardinian centenarians. Aging Clin. Exp. Res. In press.
61. NAUMOVA, E. et al. 2004. Immunological markers contributing to successful aging in Bulgarians. 39: 637-644.
62. LIO, D. et al. 2004. Opposite effects of IL-10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J. Med. Genet. In press.
63. LIO, D. et al. 2003. Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun. 4: 234-238.
64. CARUSO, C. et al. 2000. HLA, aging, and longevity: a critical reappraisal. Hum. Immunol. 61: 942-949.
65. ERLINGER, T.P. et al. 2004. C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585-590.
66. MCMILLAN, D.C. et al. 2003. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br. J. Surg. 90: 215-219.
67. TERRY, D.F. et al. 2003. Cardiovascular advantages among the offspring of centenarians. J. Gerontol. A Biol. Sci. Med. Sci. 58: M425-431.
68. NESSE, R.M., WILLIAMS, G.C. 1995. Evolution and Healing: The New Science of Darwinian Medicine. Weidenfeld & Nicolson. London.
69. MARIANI, L. et al. 2003. Chronic antigenic stress, immunosenescence and human survivorship over the 3 last centuries: heuristic value of a mathematical model. Mech. Ageing Dev. 124: 453-458.